{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:23:36Z","timestamp":1769387016874,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,24]]},"DOI":"10.7759\/cureus.102230","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:46:34Z","timestamp":1769319994000},"source":"Crossref","is-referenced-by-count":0,"title":["Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews"],"prefix":"10.7759","author":[{"given":"Arya","family":"Babul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devina","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yssra","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momina","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib","family":"Babul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Principles of Medical Statistics","author":"Hill AB","year":"1937","unstructured":"Hill AB. Principles of Medical Statistics. The Lancet, London, UK; 1937."},{"key":"ref2","unstructured":"LEQSELVI (deuruxolitinib). (2024). Accessed. December 01, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217900Orig1s000TOC.cfm."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70076","article-title":"Global burden of alopecia areata and associated diseases: a trend analysis from 1990 to 2021","volume":"24","author":"Zhou J","year":"2025","unstructured":"Zhou J, Liang L, Zhang H, Liu M, Zhu Z, Leng L, Li J. Global burden of alopecia areata and associated diseases: a trend analysis from 1990 to 2021. J Cosmet Dermatol. 2025, 24:10.1111\/jocd.70076","journal-title":"J Cosmet Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae058","article-title":"Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study","volume":"191","author":"Jeon JJ","year":"2024","unstructured":"Jeon JJ, Jung SW, Kim YH, et al.. Global, regional and national epidemiology of alopecia areata: a systematic review and modelling study. Br J Dermatol. 2024, 191:325-35. 10.1093\/bjd\/ljae058","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03302-8","article-title":"Patient-reported psychosocial burdens and quality of life and work productivity impacts among patients with clinically distinct alopecia areata severity profiles","volume":"42","author":"Hanson KA","year":"2025","unstructured":"Hanson KA, Austin J, Clayton N, et al.. Patient-reported psychosocial burdens and quality of life and work productivity impacts among patients with clinically distinct alopecia areata severity profiles. Adv Ther. 2025, 42:4556-70. 10.1007\/s12325-025-03302-8","journal-title":"Adv Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01417-y","article-title":"Comparison of Dermatology Life Quality Index scores in adults and adolescents with alopecia areata","volume":"15","author":"Hanson KA","year":"2025","unstructured":"Hanson KA, Va\u00f1\u00f3-Galv\u00e1n S, Messenger A, et al.. Comparison of Dermatology Life Quality Index scores in adults and adolescents with alopecia areata. Dermatol Ther (Heidelb). 2025, 15:1543-53. 10.1007\/s13555-025-01417-y","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf189","article-title":"Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the alopecia + me study","volume":"193","author":"Christou E","year":"2025","unstructured":"Christou E, Lalagianni N, McSweeney SM, et al.. Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the alopecia + me study. Br J Dermatol. 2025, 193:458-67. 10.1093\/bjd\/ljaf189","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70004","article-title":"The financial and time burden of alopecia areata","volume":"52","author":"Gregoire S","year":"2025","unstructured":"Gregoire S, Biba U, Sanchez K, Mesinkovska NA, Waldman M, Anderson L, Mostaghimi A. The financial and time burden of alopecia areata. J Dermatol. 2025, 52:1892-6. 10.1111\/1346-8138.70004","journal-title":"J Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78298","article-title":"Alopecia areata: understanding the pathophysiology and advancements in treatment modalities","volume":"17","author":"Abarca YA","year":"2025","unstructured":"Abarca YA, Scott-Emuakpor R, Tirth J, et al.. Alopecia areata: understanding the pathophysiology and advancements in treatment modalities. Cureus. 2025, 17:10.7759\/cureus.78298","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.10.001","article-title":"II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata","volume":"100","author":"Ramos PM","year":"2025","unstructured":"Ramos PM, Anzai A, Duque-Estrada B, et al.. II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata. An Bras Dermatol. 2025, 100:328-41. 10.1016\/j.abd.2024.10.001","journal-title":"An Bras Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15838","article-title":"Clinical presentations and comorbidities of pediatric alopecia areata","volume":"42","author":"Mistry J","year":"2025","unstructured":"Mistry J, Sibbald C. Clinical presentations and comorbidities of pediatric alopecia areata. Pediatr Dermatol. 2025, 42:5-11. 10.1111\/pde.15838","journal-title":"Pediatr Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15822","article-title":"Systemic therapies for pediatric alopecia areata","volume":"42","author":"Kalil L","year":"2025","unstructured":"Kalil L, Welch D, Heath CR, Craiglow BG. Systemic therapies for pediatric alopecia areata. Pediatr Dermatol. 2025, 42:36-42. 10.1111\/pde.15822","journal-title":"Pediatr Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae385","article-title":"British Association of Dermatologists living guideline for managing people with alopecia areata 2024","volume":"192","author":"Harries MJ","year":"2025","unstructured":"Harries MJ, Ascott A, Asfour L, et al.. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2025, 192:190-205. 10.1093\/bjd\/ljae385","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka L","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al.. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024, 38:687-94. 10.1111\/jdv.19768","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19812","article-title":"Alopecia areata: time for position statement to include new systemic therapeutic advances","volume":"38","author":"Seneschal J","year":"2024","unstructured":"Seneschal J. Alopecia areata: time for position statement to include new systemic therapeutic advances. J Eur Acad Dermatol Venereol. 2024, 38:631-2. 10.1111\/jdv.19812","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah N","year":"2020","unstructured":"Meah N, Wall D, York K, et al.. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020, 83:123-30. 10.1016\/j.jaad.2020.03.004","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013719.pub2","article-title":"Treatments for alopecia areata: a network meta-analysis","volume":"10","author":"Mateos-Haro M","year":"2023","unstructured":"Mateos-Haro M, Novoa-Candia M, S\u00e1nchez Vanegas G, et al.. Treatments for alopecia areata: a network meta-analysis. Cochrane Database Syst Rev. 2023, 10:10.1002\/14651858.CD013719.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King B","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, et al.. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021, 85:379-87. 10.1016\/j.jaad.2021.03.050","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King B","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al.. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022, 386:1687-99. 10.1056\/NEJMoa2110343","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"6","author":"King B","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al.. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023, 6:1518-29. 10.1016\/S0140-6736(23)00222-2","journal-title":"Lancet"},{"key":"ref21","unstructured":"Olumiant (baricitinib) tablets, for oral use. (2022). Accessed. November 25, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s007lbl.pdf."},{"key":"ref22","unstructured":"Litfulo (ritlecitinib) capsules, for oral use. (2023). Accessed. November 25, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215830s000lbl.pdf."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King B","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al.. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024, 91:880-8. 10.1016\/j.jaad.2024.06.097","journal-title":"J Am Acad Dermatol"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.05.1032","article-title":"62823 Optimization of deuruxolitinib dosing in adult patients with alopecia areata: results from a randomized, parallel-group, multicenter, phase 2 trial","volume":"93","author":"King B","year":"2025","unstructured":"King B, Kempers S, Mesinkovska NA, et al.. 62823 Optimization of deuruxolitinib dosing in adult patients with alopecia areata: results from a randomized, parallel-group, multicenter, phase 2 trial. J Am Acad Dermatol. 2025, 93:","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon O","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et al.. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023, 24:443-51. 10.1007\/s40257-023-00764-w","journal-title":"Am J Clin Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.3537","article-title":"Successful treatment of alopecia areata with one JAK inhibitor after failure of other JAK inhibitors","volume":"161","author":"Kalil L","year":"2025","unstructured":"Kalil L, Craiglow BG, King B. Successful treatment of alopecia areata with one JAK inhibitor after failure of other JAK inhibitors. JAMA Dermatol. 2025, 161:1285-7. 10.1001\/jamadermatol.2025.3537","journal-title":"JAMA Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King B","year":"2022","unstructured":"King B, Mesinkovska N, Mirmirani P, et al.. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022, 87:306-13. 10.1016\/j.jaad.2022.03.045","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365","article-title":"Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata","volume":"192","author":"Piliang M","year":"2025","unstructured":"Piliang M, Soung J, King B, et al.. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025, 192:215-27. 10.1093\/bjd\/ljae365","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2734","article-title":"Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial","volume":"160","author":"King B","year":"2024","unstructured":"King B, Ko J, Kwon O, et al.. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 2024, 160:1075-81. 10.1001\/jamadermatol.2024.2734","journal-title":"JAMA Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.12.008","article-title":"Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial","volume":"87","author":"Peeva E","year":"2022","unstructured":"Peeva E, Guttman-Yassky E, Banerjee A, et al.. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol. 2022, 87:390-3. 10.1016\/j.jaad.2021.12.008","journal-title":"J Am Acad Dermatol"},{"key":"ref31","article-title":"Rational and efficacy of Janus kinase inhibitor switching for alopecia areata","volume":"93","author":"Yu M","year":"2025","unstructured":"Yu M, Quan V, Li E, et al.. Rational and efficacy of Janus kinase inhibitor switching for alopecia areata. J Am Acad Dermatol. 2025, 93:","journal-title":"J Am Acad Dermatol"},{"key":"ref32","article-title":"Switching between Janus kinase inhibitors for treatment of alopecia areata","volume":"93","author":"Martin A","year":"2025","unstructured":"Martin A, Sharma D, Mack S, Kelley K, Senna M. Switching between Janus kinase inhibitors for treatment of alopecia areata. J Am Acad Dermatol. 2025, 93:","journal-title":"J Am Acad Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15062","article-title":"Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata","volume":"34","author":"Peterson D","year":"2021","unstructured":"Peterson D, Powell M, King B. Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata. Dermatol Ther. 2021, 34:10.1111\/dth.15062","journal-title":"Dermatol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.11.070","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial","author":"Tsianakas A","year":"2025","unstructured":"Tsianakas A, Passeron T, Magnolo N, et al.. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2025, 10.1016\/j.jaad.2025.11.070","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1641245","article-title":"Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients","volume":"12","author":"Kalantan M","year":"2025","unstructured":"Kalantan M, Bashrahil B, Aljuaid A, Bogari H, Samarkandy S, Jfri A. Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients. Front Med (Lausanne). 2025, 12:10.3389\/fmed.2025.1641245","journal-title":"Front Med (Lausanne)"},{"key":"ref36","unstructured":"Sun's concert hits bum note as FDA imposes partial hold 2 months after $576M buyout. (2023). Accessed. October 11, 2025: https:\/\/tinyurl.com\/6wvejuzb."},{"key":"ref37","unstructured":"Drug approval package. LEQSELVI, 8 mg tablets. (2024). Accessed: November 25, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217900Orig1s000TOC.cfm."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70185","article-title":"The relative efficacy and safety of monotherapies for alopecia areata: a network meta-analysis study","volume":"24","author":"Gupta AK","year":"2025","unstructured":"Gupta AK, Bamimore MA, Mirmirani P, Piguet V, Talukder M. The relative efficacy and safety of monotherapies for alopecia areata: a network meta-analysis study. J Cosmet Dermatol. 2025, 24:10.1111\/jocd.70185","journal-title":"J Cosmet Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1576553","article-title":"Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis","volume":"16","author":"Qi Z","year":"2025","unstructured":"Qi Z, Li Y. Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis. Front Pharmacol. 2025, 16:10.3389\/fphar.2025.1576553","journal-title":"Front Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17959","article-title":"Comparative efficacy of Janus kinase inhibitors indicated for severe alopecia areata: a Bayesian network meta-analysis and matching-adjusted indirect comparison","author":"Babul A","year":"2025","unstructured":"Babul A, Mehta D, Soliman Y, Hussain M, Babul N. Comparative efficacy of Janus kinase inhibitors indicated for severe alopecia areata: a Bayesian network meta-analysis and matching-adjusted indirect comparison. J Dermatol. 2025, 10.1111\/1346-8138.17959","journal-title":"J Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman CI","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012, 18:527-39. 10.18553\/jmcp.2012.18.7.527","journal-title":"J Manag Care Pharm"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.677419","article-title":"Effect of dosing frequency on chronic cardiovascular disease medication adherence","volume":"28","author":"Coleman CI","year":"2012","unstructured":"Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012, 28:669-80. 10.1185\/03007995.2012.677419","journal-title":"Curr Med Res Opin"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00462.x","article-title":"The DIACOM study (effect of dosing frequency of oral antidiabetic agents on the compliance and biochemical control of type 2 diabetes)","volume":"7","author":"Kardas P","year":"2005","unstructured":"Kardas P. The DIACOM study (effect of dosing frequency of oral antidiabetic agents on the compliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005, 7:722-8. 10.1111\/j.1463-1326.2004.00462.x","journal-title":"Diabetes Obes Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-013-0020-5","article-title":"Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism","volume":"6","author":"Lalibert\u00e9 F","year":"2013","unstructured":"Lalibert\u00e9 F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013, 6:213-24. 10.1007\/s40271-013-0020-5","journal-title":"Patient"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S417180","article-title":"Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia","volume":"17","author":"Lu X","year":"2023","unstructured":"Lu X, Emond B, Morrison L, et al.. Real-world comparison of first-line treatment adherence between single-agent ibrutinib and acalabrutinib in patients with chronic lymphocytic leukemia. Patient Prefer Adherence. 2023, 17:2073-84. 10.2147\/PPA.S417180","journal-title":"Patient Prefer Adherence"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2014.01.013","article-title":"The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis","volume":"33","author":"Caldeira D","year":"2014","unstructured":"Caldeira D, Vaz-Carneiro A, Costa J. The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis. Rev Port Cardiol. 2014, 33:431-7. 10.1016\/j.repc.2014.01.013","journal-title":"Rev Port Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.09.053","article-title":"Use of ritlecitinib in patients with alopecia areata refractory to tofacitinib or baricitinib: a single-center retrospective cohort study","volume":"94","author":"Huang J","year":"2026","unstructured":"Huang J, Jian J, Li M, et al.. Use of ritlecitinib in patients with alopecia areata refractory to tofacitinib or baricitinib: a single-center retrospective cohort study. J Am Acad Dermatol. 2026, 94:351-3. 10.1016\/j.jaad.2025.09.053","journal-title":"J Am Acad Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-03848-1","article-title":"Jak inhibitor intraclass switch in alopecia areata patients: a retrospective review of cases at an academic center","volume":"317","author":"Silva I","year":"2025","unstructured":"Silva I, Khattri S. Jak inhibitor intraclass switch in alopecia areata patients: a retrospective review of cases at an academic center. Arch Dermatol Res. 2025, 317:10.1007\/s00403-025-03848-1","journal-title":"Arch Dermatol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452520-evidence-synthesis-gone-awry-the-perils-of-aggregating-ineffective-or-unsafe-doses-in-alopecia-areata-reviews","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:46:36Z","timestamp":1769319996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452520-evidence-synthesis-gone-awry-the-perils-of-aggregating-ineffective-or-unsafe-doses-in-alopecia-areata-reviews"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.102230","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}